The overall goal of the Hawai?i Minority/Underserved NCORP is to provide access and facilitate enrollment of Hawaii?s diverse, multiethnic population to NCI sponsored trials. Thus we will enhance accrual of underrepresented populations including Native Hawaiians, other Pacific Islanders, Asian-Americans (Chinese, Japanese, Filipino and Korean), adolescents and young adults (AYA), the elderly and sexual and gender minorities (LGBTQ). Our NCORP is the primary provider of NCI clinical trials and cancer care delivery research (CCDR) in the State of Hawai?i where nearly 75% of the population is comprised of multiple minority racial/ethnic groups. The Hawai?i M/U NCORP supports an integrated network of affiliates and sub-affiliates with the extensive menu of cancer studies, research infrastructure and data management. Our NCORP has successfully extended CCDR studies from the originally designated sites to other hospital affiliate sites with plans to further extend them to physician office sites. We solicit community input from Native Hawaiian and LGBTQ advocates to review the suitability of trials as well as to address their healthcare needs. Non medical oncology community investigators and staff have leadership responsibility in imaging, prevention and CCDR studies. Our NCORP leaders have extensive experience in cancer clinical trials, health care delivery and disparities. They have served on multiple NCI committees. Participation in NCI?s personalized medicine, cancer control, prevention, treatment and CCDR research will further reduce cancer health care disparities and the cancer burden for the people of Hawai?i and beyond.

Public Health Relevance

The Hawai?i Minority/Underserved NCORP aims to: 1) conduct cancer clinical trials and cancer care delivery research, 2) continue contributing to NCORP research bases and NCI priorities, and 3) enhance participation of Hawaii?s diverse multiethnic and at risk population in NCI sponsored trials in order to reduce health care disparities and the burden of cancer for the people of Hawai?i and elsewhere. !

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Clinical Research Cooperative Agreements - Single Project (UG1)
Project #
2UG1CA189804-06
Application #
9774578
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Pak, Jennifer Soyoung
Project Start
2014-08-01
Project End
2025-07-31
Budget Start
2019-08-09
Budget End
2020-07-31
Support Year
6
Fiscal Year
2019
Total Cost
Indirect Cost
Name
University of Hawaii
Department
Type
Organized Research Units
DUNS #
965088057
City
Honolulu
State
HI
Country
United States
Zip Code
96822
Sparano, Joseph A; Gray, Robert J; Makower, Della F et al. (2018) Adjuvant Chemotherapy Guided by a 21-Gene Expression Assay in Breast Cancer. N Engl J Med 379:111-121
Henry, N Lynn; Unger, Joseph M; Schott, Anne F et al. (2018) Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol 36:326-332
Hussain, Maha; Tangen, Catherine M; Thompson Jr, Ian M et al. (2018) Phase III Intergroup Trial of Adjuvant Androgen Deprivation With or Without Mitoxantrone Plus Prednisone in Patients With High-Risk Prostate Cancer After Radical Prostatectomy: SWOG S9921. J Clin Oncol 36:1498-1504
Persky, Daniel O; Li, Hongli; Rimsza, Lisa M et al. (2018) A phase I/II trial of vorinostat (SAHA) in combination with rituximab-CHOP in patients with newly diagnosed advanced stage diffuse large B-cell lymphoma (DLBCL): SWOG S0806. Am J Hematol 93:486-493
Kleckner, Ian R; Kamen, Charles; Gewandter, Jennifer S et al. (2018) Effects of exercise during chemotherapy on chemotherapy-induced peripheral neuropathy: a multicenter, randomized controlled trial. Support Care Cancer 26:1019-1028
Flaig, Thomas W; Plets, Melissa; Hussain, Maha H A et al. (2017) Abiraterone Acetate for Metastatic Prostate Cancer in Patients With Suboptimal Biochemical Response to Hormone Induction. JAMA Oncol 3:e170231
Chung, Vincent; McDonough, Shannon; Philip, Philip A et al. (2017) Effect of Selumetinib and MK-2206 vs Oxaliplatin and Fluorouracil in Patients With Metastatic Pancreatic Cancer After Prior Therapy: SWOG S1115 Study Randomized Clinical Trial. JAMA Oncol 3:516-522
Sekeres, Mikkael A; Othus, Megan; List, Alan F et al. (2017) Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol 35:2745-2753
Moinpour, Carol M; Unger, Joseph M; Ganz, Patricia A et al. (2017) Seven-year follow-up for energy/vitality outcomes in early stage Hodgkin's disease patients treated with subtotal lymphoid irradiation versus chemotherapy plus radiation: SWOG S9133 and its QOL companion study, S9208. J Cancer Surviv 11:32-40
Heinrich, Michael C; Rankin, Cathryn; Blanke, Charles D et al. (2017) Correlation of Long-term Results of Imatinib in Advanced Gastrointestinal Stromal Tumors With Next-Generation Sequencing Results: Analysis of Phase 3 SWOG Intergroup Trial S0033. JAMA Oncol 3:944-952

Showing the most recent 10 out of 17 publications